ParcelBio
parcelbio.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$13M
1 round on record
Latest round
$13M
Seed · May 2026 · 4 mo ago
Backers
1
Y Combinator
The money's age
Fresh money
4 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 7
Raised a round Seed $13M · led by Breyer Capital · Pulse 2.0
Jan 2024
Went through Y Combinator
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | May 2026 | $13M | Breyer Capital lead, General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator Similar startupsby what they do, their industry and backers
艾博生物成立于2019年1月，是一家专注于信使核糖核酸（mRNA）药物研发的临床期创新型生物医药公司，拥有业界领先并具有自主知识产权的mRNA和纳米递送技术平台。公司已建立了丰富的产品管线，涵盖传染病防治和肿瘤免疫等领域。.
THE FIRST CELL-BASED mRNA THERAPEUTICS PLATFORM. Synthetic mRNA has reached its limits. Our cell-based mRNA design and manufacturing…
Arpelos designs multivalent medicines with transformative outcomes.
Protein Splicing to Develop the Next Generation of Genetic Medicines.
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
Unlocking the potential of the immune system. IMU.
Overview
Elevated mRNA for transformative medicines. mRNA has already changed medicine. But the next generation of mRNA medicines – therapies that reprogram the immune system, kill tumors, and replace missing proteins – require a step-change in potency and durability. Conventional mRNA can't get there.
News
ParcelBio获得1300万美元种子轮融资_腾讯新闻
ParcelBio是一家mRNA药物研发商主要从事mRNA药物研发业务其专有的APEXm平台提供自身免疫性疾病的体内CAR-T、肿瘤学和编码蛋白疗法服务近日ParcelBio宣布完成1300万美元种子轮融资由Breyer Capital领投General Catalyst、Y Combinator、Metaplanet、SurgePoint Capital、ZAKA VC和其他投资者参与...
Read more
Report
ParcelBio完成1300万美元种子轮融资- DoNews快讯
2026年5月美国mRNA药物研发商ParcelBio宣布完成1300万美元种子轮融资本轮融资由Breyer Capital领投General Catalyst、Y Combin ...
Read more
Report
ParcelBio: $13 Million Seed Financing Raised To Advance Next-Generation mRNA Medicines
ParcelBio launched with $13 million in seed financing led by Breyer Capital, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and additional investors.
Read more
Report
Seed financing at Parcelbio to advance mRNA medicines
Parcelbio has raised $13 million in seed financing to continue its development of a new class of potent and durable mRNA medicines. The financing will support development of Parcelbio's proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform
Read more
Report
Financials
Total raised
$13M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2026 | $13M | Details |